<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181633</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-103</org_study_id>
    <secondary_id>2017-000665-79</secondary_id>
    <secondary_id>U1111-1196-0653</secondary_id>
    <nct_id>NCT03181633</nct_id>
  </id_info>
  <brief_title>A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
  <official_title>An Open-Label Study to Evaluate Efficacy and Safety of Long-Term Treatment With ACH-0144471 in Participants Who Completed Clinical Study ACH471-100</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and efficacy of ACH-0144471 in&#xD;
      participants with paroxysmal nocturnal hemoglobinuria (PNH) who have demonstrated clinical&#xD;
      benefit from ACH-0144471 in Study ACH471-100. This study is designed to include up to 12&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">August 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And AEs Leading To Discontinuation</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Lactate Dehydrogenase (LDH) Levels</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin (Hgb) Levels</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Red Blood Cell (RBC) Transfusions</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte Counts</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment Of Chronic Illness Therapy (FACIT) Fatigue Scale Scores</measure>
    <time_frame>Week 1, Week 13, Week 37, and then every 6 months through study completion, an average of 2 years</time_frame>
    <description>FACIT score ranges from 0-52, with a higher score indicating less Fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization For Research And Treatment (EORTC) Cancer Core Quality Of Life Questionnaire (QLQ-C30) Scores</measure>
    <time_frame>Week 1, Week 13, Week 37, and then every 6 months through study completion, an average of 2 years</time_frame>
    <description>EORTC score ranges from 0-100, with higher scores in any of the three measures indicating: a high healthy level of functioning, or a high global health status or quality of life, or a high level of symptomatology / problems.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>ACH-0144471</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive ACH-0144471 during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471</intervention_name>
    <description>ACH-0144471 will be administered to all participants enrolled in the study.</description>
    <arm_group_label>ACH-0144471</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study designed to include up to 12 participants who completed treatment in Study&#xD;
             ACH471-100 and demonstrated clinical benefit from ACH-0144471 with no significant&#xD;
             safety or tolerability concerns.&#xD;
&#xD;
          -  Negative pregnancy test for females prior to dosing and throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have developed any clinically relevant co-morbidities while participating in Study&#xD;
             ACH471-100 that would make the participant inappropriate for the continuation of&#xD;
             treatment with ACH-0144471, in the opinion of the Investigator.&#xD;
&#xD;
          -  Have developed any clinically significant laboratory abnormalities while participating&#xD;
             in Study ACH471-100 that, in the opinion of the Investigator, would make the&#xD;
             participant inappropriate for the study or put the participant at undue risk.&#xD;
&#xD;
          -  Females who are pregnant, nursing, or planning to become pregnant during the study or&#xD;
             within 90 days of study drug administration or participants with a female partner who&#xD;
             is pregnant, nursing, or planning to become pregnant during the study or within 90&#xD;
             days of study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <keyword>Paroxysmal</keyword>
  <keyword>Hemoglobinuria</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>ALXN2040</keyword>
  <keyword>Danicopan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

